Table 2 Result summary of all investigated samples
| Â | BRCA1/2 variants | HRD-associated variants | Â | TP53 variants | ||
|---|---|---|---|---|---|---|
likely pathogenic/ pathogenic | likely pathogenic/ pathogenic | VUS (predicted damaging) | VUS (predicted tolerated) | likely benign/ benign + wild type | likely pathogenic/ pathogenic | |
Ovarian Cancer (n = 63) | 16 (25.4%) | 15 (23.8%) | 4 (6.3%) | 7 (11.1%) | 21 (33.3%) | 49 (77.8%) |
Breast Cancer (n = 13) | 4 (30.8%) | 3 (23.1%) | 0 (0%) | 2 (15.4%) | 4 (30.8%) | 9 (69.2%) |
Pancreatic Cancer (n = 9) | 0 (0%) | 2 (22.2%) | 1 (11.1%) | 1 (11.1%) | 5 (55.6%) | 7 (77.8%) |
Prostate Cancer (n = 5) | 0 (0%) | 2 (40.0%) | 0 (0%) | 1 (20.0%) | 2 (40.0%) | 1 (20.0%) |
Total (n = 90) | 20 (22.2%) | 22 (24.4%) | 5 (5.6%) | 11 (12.2%) | 32 (35.6%) | 66 (73.3%) |